Acytronix revolutionizes the purification of extracellular vesicles (EVs) with a mission to advance diagnostics and therapeutics. EVs are nano-sized vesicles secreted by cells in the body. They are bioactive, reflect the characteristics of their tissue of origin, and are distributed in bodily fluids.

Recognized as next-generation biomarkers and therapeutic agents, EVs hold tremendous potential. However, the need to isolate them from complex native matrices has limited their biomedical applications.

Acytronix, an ETH spin-off based in Schlieren, is led by CEO Dr. Vadim Krivitsky and CTO Dr. Adva Krivitsky. The company has developed a portable, easy-to-use device for isolating EVs directly from raw physiological fluids. This patent-protected device offers significant advantages over conventional EV isolation methods, enabling high-throughput separation of EV sub-populations based on surface marker expression—advancing EV-based liquid biopsy. Additionally, it uniquely allows EVs to be loaded with therapeutics on a single platform, opening new avenues for drug delivery applications.